Shares in Stratagene rose 22.4 percent over the five-day trading period ended Tuesday, far outgaining any of the other stocks that comprise the BCW Index. The gain is likely the result of investors believing that a recent sell off was unwarranted.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.